Future Platforms

Future areas of research and development include solutions for microbiome-related health issues:


cardiovascular disease/hypertension

Heart disease is one of the most common causes of death worldwide. Intestinal flora affect blood sugar and heart health by reducing cholesterol levels, blood pressure and inflammation. Realize products based on microbiome restoration and modulation are being developed to treat cardiovascular and hypertension issues.


SIBO (small bacterial overgrowith)

SIBO is a condition related to excess numbers of bacteria in the small intestine, and can be linked to Irritable Bowel Syndrome, Research clearly shows that certain microbes are very effective at treating SIBO and related issues. Realize Therapeutics is developing formulas to address these health problems.



Metabolic endotoxemia is a condition estimated to affect 33% of the western world. This occurs when bacterial metabolites such as lipopolysaccharides enter the bloodstream and have been highly correlated to a variety of chronic diseases. That this condition begins with imbalanced intestinal flora makes it particularly susceptible to Realize Therapeutics treatment strategy.

notify me of new developments

Keep up to date with new developments from Realize Therapeutics